92,078 Shares in Wave Life Sciences Ltd (WVE) Purchased by Artal Group S.A.

Artal Group S.A. bought a new stake in Wave Life Sciences Ltd (NASDAQ:WVE) in the fourth quarter, HoldingsChannel.com reports. The fund bought 92,078 shares of the company’s stock, valued at approximately $3,232,000.

Several other hedge funds also recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Wave Life Sciences by 60.0% in the fourth quarter. BlackRock Inc. now owns 934,733 shares of the company’s stock valued at $32,810,000 after buying an additional 350,570 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Wave Life Sciences by 15.5% in the fourth quarter. Bank of New York Mellon Corp now owns 57,388 shares of the company’s stock valued at $2,015,000 after buying an additional 7,695 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Wave Life Sciences in the fourth quarter valued at about $316,000. Bailard Inc. acquired a new stake in shares of Wave Life Sciences in the fourth quarter valued at about $2,773,000. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Wave Life Sciences by 31.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 74,421 shares of the company’s stock valued at $2,613,000 after buying an additional 17,884 shares in the last quarter. Institutional investors and hedge funds own 73.60% of the company’s stock.

Shares of Wave Life Sciences Ltd (WVE) opened at $54.70 on Friday. Wave Life Sciences Ltd has a 12 month low of $15.15 and a 12 month high of $55.00. The company has a current ratio of 11.50, a quick ratio of 11.50 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1,452.03, a P/E ratio of -15.45 and a beta of 0.93.

In other Wave Life Sciences news, insider Chandra Vargeese sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 53.00% of the stock is owned by company insiders.

A number of equities research analysts have recently issued reports on WVE shares. BidaskClub upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. Mizuho set a $34.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a research note on Saturday, October 21st. TheStreet upgraded Wave Life Sciences from a “d+” rating to a “c-” rating in a research note on Friday, January 5th. Leerink Swann restated an “outperform” rating and set a $53.00 price objective (up previously from $42.00) on shares of Wave Life Sciences in a research note on Wednesday, November 15th. Finally, Zacks Investment Research lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $41.75.

TRADEMARK VIOLATION WARNING: “92,078 Shares in Wave Life Sciences Ltd (WVE) Purchased by Artal Group S.A.” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/18/92078-shares-in-wave-life-sciences-ltd-wve-purchased-by-artal-group-s-a.html.

Wave Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd (NASDAQ:WVE).

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply